JAK Inhibitors Start To Come Of Age In Rheumatoid Arthritis

Oral class has gotten off to slow start, but data for range of JAK inhibitors – including Lilly’s once-daily baricitinib – presented at American College of Rheumatology meeting are encouraging.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America